Comparative Pharmacology
Head-to-head clinical analysis: CEFPIRAMIDE SODIUM versus CEFTAZIDIME IN DEXTROSE CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFPIRAMIDE SODIUM versus CEFTAZIDIME IN DEXTROSE CONTAINER.
CEFPIRAMIDE SODIUM vs CEFTAZIDIME IN DEXTROSE CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefpiramide sodium is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
1-2 g IV every 12 hours; maximum 8 g/day
1-2 g intravenously every 8 hours.
None Documented
None Documented
4-5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl < 20 mL/min)
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: 10-20%
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic